SCHEMBL933344

SCHEMBL933344

CN(C)C1CCN(c2nc[c]cn2)CC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL3 Q96JM7 2/20 0.41
PTPN11 Q06124 1/20 0.40
CCR4 P51679 1/20 0.36
MAP4K4 O95819 1/20 0.35
HRH4 Q9H3N8 2/20 0.35
HRH3 Q9Y5N1 2/20 0.35
KDM4E B2RXH2 1/20 0.34
CYP2C19 P33261 1/20 0.34
KCNH2 Q12809 3/20 0.34
CYP2D6 P10635 2/20 0.34
HRH1 P35367 2/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
HDAC6 Q9UBN7 1/20 0.34
DYRK1A Q13627 1/20 0.33
PIK3CD O00329 1/20 0.33
PIK3C2B O00750 1/20 0.33
PIK3CA P42336 1/20 0.33
PIK3CB P42338 1/20 0.33
MTOR P42345 1/20 0.33
PIK3CG P48736 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10145970 0.81 KDM4E (0.51) PTPN11KDM4ECYP2C19DYRK1AGPR119
SCHEMBL16003398 0.79 KCNH2 (0.47) L3MBTL3PTPN11CCR4MAP4K4KCNH2
SCHEMBL933191 0.78 MAP4K4 (0.39) L3MBTL3PTPN11MAP4K4HRH4HRH3
SCHEMBL31217395 0.77 PTPN11 (0.45) L3MBTL3PTPN11CCR4KDM4EKCNH2
SCHEMBL20478069 0.72 GPR119 (0.40) KDM4ECYP2C19KCNH2GPR119
SCHEMBL2037934 0.72 SMN1; SMN2 (0.40) KDM4EHRH1L3MBTL1
SCHEMBL28028147 0.71 HRH4 (0.37) L3MBTL3PTPN11MAP4K4HRH4HRH3
SCHEMBL933564 0.71 HRH4 (0.43) HRH4
SCHEMBL5545660 0.70 L3MBTL3 (0.43) L3MBTL3KCNH2CYP2D6HRH1L3MBTL1
SCHEMBL28220125 0.70 MAP4K4 (0.46) MAP4K4HRH4HRH3HDAC6DYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3072890-B1 Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy MEI PHARMA INC (US) 2018-10-17 EP disclosed
EP-3072890-A1 Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy MEI Pharma, Inc. (US) 2016-09-28 EP disclosed
US-8486939-B2 Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy PATHWAY THERAPEUTICS INC. (US) 2013-07-16 US disclosed
EP-2532659-A1 Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy Pathway Therapeutics, Inc. (US) 2012-12-12 EP disclosed
EP-2451802-A1 PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLES AND THEIR USE IN CANCER THERAPY Pathway Therapeutics, Inc. (US) 2012-05-16 EP disclosed
US-20110009405-A1 PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLES AND THEIR USE IN CANCER THERAPY PATHWAY THERAPEUTICS LIMITED (NZ) 2011-01-13 US disclosed
WO-2011005119-A1 PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLES AND THEIR USE IN CANCER THERAPY PATHWAY THERAPEUTICS LIMITED (NZ) 2011-01-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110009405-A1 PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLES AND THEIR USE IN CANCER THERAPY TYMP, TYMS, CCNI L3MBTL3 3208/4885PTPN11 4190/4885CCR4 2810/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.